Abstract

Background: Sporadic venous malformation (VM) and angiomatosis of soft tissue (AST) are benign, congenital vascular anomalies affecting venous vasculature. Depending on the size and location of the lesion, symptoms vary from motility disturbances to pain and disfigurement. Due to high recurrence of the lesions more effective therapies are needed.

Methods: As targeting stromal cells has been an emerging concept in anti-angiogenic therapies, here, by using VM/AST patient samples, RNA-sequencing, cell culture techniques and a xenograft mouse model, we investigated the crosstalk of endothelial cells (EC) and fibroblasts and its effect on vascular lesion growth.

Results: We report, for the first time, expression and secretion of transforming growth factor A (TGFA) in ECs or intervascular stromal cells in AST and VM lesions. TGFA induced secretion of VEGF-A paracrinally, and regulated EC proliferation. Oncogenic PIK3CA variant in p.H1047R, a common somatic mutation found in these lesions, increased TGFA expression, enrichment of hallmark hypoxia, and in a mouse xenograft model, lesion size and vascularization. Treatment with afatinib, a pan-ErbB tyrosine-kinase inhibitor, decreased vascularization and lesion size in mouse xenograft model with ECs expressing oncogenic PIK3CA p.H1047R variant and fibroblasts.

Conclusions: Based on the data, we suggest that targeting of both intervascular stromal cells and ECs is a potential treatment strategy for vascular lesions having a fibrous component.

Funding: Academy of Finland, Ella and Georg Ehnrooth foundation, the ERC grants, Sigrid Jusélius Foundation, Finnish Foundation for Cardiovascular Research, Jane and Aatos Erkko Foundation, and Department of Musculosceletal and Plastic Surgery, Helsinki University Hospital.

Data availability

RNA-seq data has been submitted to NCBI Gene Expression Omnibus under accession numbers GSE130807 and GSE196311 (GEO reviewer access tokens; wbivkayaxhojdqp and mbehiikgvtmfryh, respectively).

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Suvi Jauhiainen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  2. Henna Ilmonen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  3. Pia Vuola

    Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  4. Heta Rasinkangas

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  5. Heidi H Pulkkinen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  6. Sara Keränen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  7. Miika Kiema

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  8. Jade J Liikkanen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  9. Nihay Laham Karam

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8718-4612
  10. Svetlana Laidinen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  11. Mustafa Beter

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  12. Einari Aavik

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3018-9521
  13. Kimmo Lappalainen

    Department of Radiology, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  14. Jouko Lohi

    Department of Pathology, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  15. Johanna Aronniemi

    Department of Radiology, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  16. Tiit Örd

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
  17. Minna U Kaikkonen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6294-0979
  18. Päivi Salminen

    Department of Pediatric Surgery, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  19. Erkki Tukiainen

    Department of Plastic Surgery, Helsinki University Hospital, Helsinki, Finland
    Competing interests
    The authors declare that no competing interests exist.
  20. Seppo Ylä-Herttuala

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7593-2708
  21. Johanna P Laakkonen

    AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
    For correspondence
    johanna.p.laakkonen@uef.fi
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8556-9727

Funding

Academy of Finland (328835)

  • Johanna P Laakkonen

ERC grant (GA670951)

  • Seppo Ylä-Herttuala

ERC grant (802825)

  • Minna U Kaikkonen

Sigrid Jusélius Foundation

  • Seppo Ylä-Herttuala

Sigrid Jusélius Foundation

  • Minna U Kaikkonen

Finnish Foundation for Cardiovascular Research

  • Johanna P Laakkonen

Finnish Foundation for Cardiovascular Research

  • Seppo Ylä-Herttuala

Finnish Foundation for Cardiovascular Research

  • Minna U Kaikkonen

Jane and Aatos Erkko Foundation

  • Minna U Kaikkonen

Department of Musculosceletal and Plastic Surgery, Helsinki University Hospital

  • Pia Vuola

Academy of Finland (321535)

  • Johanna P Laakkonen

Academy of Finland (353376)

  • Johanna P Laakkonen

Academy of Finland (287478)

  • Minna U Kaikkonen

Academy of Finland (294073)

  • Minna U Kaikkonen

Ella and Georg Ehnrooth foundation

  • Johanna P Laakkonen

CoE of Cardiovascular and Metabolic Disease (307402)

  • Seppo Ylä-Herttuala

GeneCellNano Flagship Program (337120)

  • Johanna P Laakkonen

GeneCellNano Flagship Program (337120)

  • Seppo Ylä-Herttuala

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experiments were approved by National Experimental Animal Board of Finland (Decision No Esavi-2019-004672) and carried out in accordance with guidelines of the Finnish Act on Animal Experimentation.

Human subjects: Patient sample collection was approved by the Ethical Committee of the Helsinki University hospital, Helsinki, Finland (Decision No 127/13/03/02/2010 and No 1394/2020). Control sample collection was approved by the Research Ethics Committee of the Northern Savo Hospital District, Kuopio, Finland (Decision No 139/2015). Umbilical cord collection for HUVEC isolation was performed with approval from the Research Ethics Committee of the Northern Savo Hospital District, Kuopio, Finland (Decision No 341/2015). Informed consent, and consent to publish, was obtained from all patients included in the study.

Copyright

© 2023, Jauhiainen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 913
    views
  • 124
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Suvi Jauhiainen
  2. Henna Ilmonen
  3. Pia Vuola
  4. Heta Rasinkangas
  5. Heidi H Pulkkinen
  6. Sara Keränen
  7. Miika Kiema
  8. Jade J Liikkanen
  9. Nihay Laham Karam
  10. Svetlana Laidinen
  11. Mustafa Beter
  12. Einari Aavik
  13. Kimmo Lappalainen
  14. Jouko Lohi
  15. Johanna Aronniemi
  16. Tiit Örd
  17. Minna U Kaikkonen
  18. Päivi Salminen
  19. Erkki Tukiainen
  20. Seppo Ylä-Herttuala
  21. Johanna P Laakkonen
(2023)
ErbB signalling is a potential therapeutic target for vascular lesions with fibrous component
eLife 12:e82543.
https://doi.org/10.7554/eLife.82543

Share this article

https://doi.org/10.7554/eLife.82543

Further reading

    1. Cell Biology
    Zewei Zhao, Longyun Hu ... Zhonghan Yang
    Research Article

    The induction of adipose thermogenesis plays a critical role in maintaining body temperature and improving metabolic homeostasis to combat obesity. β3-adrenoceptor (β3-AR) is widely recognized as a canonical β-adrenergic G-protein-coupled receptor (GPCR) that plays a crucial role in mediating adipose thermogenesis in mice. Nonetheless, the limited expression of β3-AR in human adipocytes restricts its clinical application. The objective of this study was to identify a GPCR that is highly expressed in human adipocytes and to explore its potential involvement in adipose thermogenesis. Our research findings have demonstrated that the adhesion G-protein-coupled receptor A3 (ADGRA3), an orphan GPCR, plays a significant role in adipose thermogenesis through its constitutively active effects. ADGRA3 exhibited high expression levels in human adipocytes and mouse brown fat. Furthermore, the knockdown of Adgra3 resulted in an exacerbated obese phenotype and a reduction in the expression of thermogenic markers in mice. Conversely, Adgra3 overexpression activated the adipose thermogenic program and improved metabolic homeostasis in mice without exogenous ligand. We found that ADGRA3 facilitates the biogenesis of beige human or mouse adipocytes in vitro. Moreover, hesperetin was identified as a potential agonist of ADGRA3, capable of inducing adipocyte browning and ameliorating insulin resistance in mice. In conclusion, our study demonstrated that the overexpression of constitutively active ADGRA3 or the activation of ADGRA3 by hesperetin can induce adipocyte browning by Gs-PKA-CREB axis. These findings indicate that the utilization of hesperetin and the selective overexpression of ADGRA3 in adipose tissue could serve as promising therapeutic strategies in the fight against obesity.

    1. Cell Biology
    2. Chromosomes and Gene Expression
    Bethany M Bartlett, Yatendra Kumar ... Wendy A Bickmore
    Research Article Updated

    During oncogene-induced senescence there are striking changes in the organisation of heterochromatin in the nucleus. This is accompanied by activation of a pro-inflammatory gene expression programme – the senescence-associated secretory phenotype (SASP) – driven by transcription factors such as NF-κB. The relationship between heterochromatin re-organisation and the SASP has been unclear. Here, we show that TPR, a protein of the nuclear pore complex basket required for heterochromatin re-organisation during senescence, is also required for the very early activation of NF-κB signalling during the stress-response phase of oncogene-induced senescence. This is prior to activation of the SASP and occurs without affecting NF-κB nuclear import. We show that TPR is required for the activation of innate immune signalling at these early stages of senescence and we link this to the formation of heterochromatin-enriched cytoplasmic chromatin fragments thought to bleb off from the nuclear periphery. We show that HMGA1 is also required for cytoplasmic chromatin fragment formation. Together these data suggest that re-organisation of heterochromatin is involved in altered structural integrity of the nuclear periphery during senescence, and that this can lead to activation of cytoplasmic nucleic acid sensing, NF-κB signalling, and activation of the SASP.